Last updated on December 2017

A Randomized, Double-Blind, Placebo-Controlled Study of Galcanezumab in Patients 6 to 17 Years of Age with Episodic Migraine – the REBUILD Study


Brief description of study

To assess the single dose PK of galcanezumab administered via subcutaneous injection in a population of pediatric patients aged 6 to 17 years with migraine

Clinical Study Identifier: TX155191

Contact Investigators or Research Sites near you

Start Over

Arifulla Khan, MD

Northwest Clinical Research Center
Bellevue, WA USA
  Connect »